Navigation Links
BD Announces CE Marking of BD ProbeTec™ Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
Date:6/23/2009

This next-generation BD Viper System with XTR technology enables laboratories to process a higher volume of tests automatically from swabs or urine samples, with significantly less labour and more reliable test results. This improvement in process efficiency may lead to a higher number of accurate diagnoses and more appropriate patient care for the two most common sexually transmitted infections - Chlamydia and gonorrhea. If left untreated, these infections in women can lead to pelvic inflammatory disease, infertility, ectopic pregnancy and chronic pelvic pain.

Oxford, UK (PRWeb UK) June 23, 2009 -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company ), recently announced the CE marking of the BD ProbeTec™ Chlamydia trachomatis (CT) Qx Amplified DNA Assay and the BD ProbeTec™ Neisseria gonorrhoeae (GC) Qx Amplified DNA Assay for use on the BD Viper™ System with XTR™ Technology.

This next-generation BD Viper System with XTR technology enables laboratories to process a higher volume of tests automatically from swabs or urine samples, with significantly less labour and more reliable test results. This improvement in process efficiency may lead to a higher number of accurate diagnoses and more appropriate patient care for the two most common sexually transmitted infections - Chlamydia and gonorrhea. If left untreated, these infections in women can lead to pelvic inflammatory disease, infertility, ectopic pregnancy and chronic pelvic pain.

"BD ProbeTec Qx Amplified DNA Assays are designed to meet the needs of today's high-volume clinical laboratories, providing extremely reliable detection of Chlamydia trachomatis and Neisseria gonorrhoeae," said Jonathan Barrett, Business Director, UK and Ireland, BD Diagnostics - Diagnostic Systems. "Running these advanced molecular assays on the BD Viper System with advanced XTR technology offers laboratories total system integrity that helps assure reliability in their systems, reagents and results."

The fully automated system processes up to 736 patient samples in a single work shift. It offers the least hands-on time for setup, sample extraction, workflow and maintenance. One operator can fully execute all of the functions required to report results with several BD Viper Systems operating concurrently.

The World Health Organization estimates that 92 million new cases of Chlamydia and 62 million new cases of gonorrhea are diagnosed each year.1 Genital Chlamydia is the most commonly diagnosed sexually transmitted infection in genitor-urinary medicine clinics in the United Kingdom. In 2006, there were more than 113,500 cases of uncomplicated infection, a rise of four percent from 2005.2 The detection of Chlamydia infection has risen steadily in men and women since the mid-1990s, due mainly to increased testing and improved diagnostic tests. Rates of gonococcal infection have declined in both men and women since 2003, with an overall drop of one percent (19,248 to 19,007) in 2006.

About BD ProbeTec Qx Assays and the BD Viper System with XTR Technology
The new BD Viper System with XTR Technology is designed to provide high-volume customers with highly reliable detection of Chlamydia and gonorrhea at a high throughput rate using an internal extraction control and process verification. When tested with the BD Viper System with XTR Technology, the BD ProbeTec CT Qx and GC Qx Amplified DNA Assays use BD proprietary ferric oxide, FOX™ Extraction, and Strand Displacement Amplification technologies for the direct, qualitative detection of Chlamydia trachomatis and Neisseria gonorrhoeae DNA. The tests are performed on clinician-collected female endocervical and male urethral swab specimens, patient-collected vaginal swab specimens (in a clinical setting), and male and female urine specimens. These assays are indicated for use with asymptomatic4 and symptomatic individuals to aid in the diagnosis of chlamydial and gonococcal urogenital disease.

About BD
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit http://www.bd.com/uk

1 World Health Organization. (2001). Global prevalence and incidence of selected curable sexually transmitted infections overview and estimates. Retrieved 5 January 2009 from http://www.who.int/hiv/pub/sti/who_hiv_aids_2001.02.pdf
2 UK Statistics Authority. (2008). Chapter 7: Health social trends 38. Retrieved January 5, 2009 from http://www.statistics.gov.uk/downloads/theme_social/Social_Trends38/ST38_Ch07.pdf
3 Health Protection Agency. (2007, July, 20). Sexually transmitted infection diagnoses and services provided in genitourinary medicine clinics in the country-region in 2006. Retrieved January 5, 2009 from http://www.hpa.org.uk/hpr/archives/2007/news2007/news2907.htm
4 Indications for asymptomatic males for GC have not been established

###

Read the full story at http://www.prweb.com/releases/2009/06/prweb2560934.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... SensorInsight ®, ... Sigfox in the U.S.A. to offer Internet of Things (IoT) solutions based ... large-scale environmental sensor deployments such as monitoring solutions used to detect potentially hazardous ...
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading ... a Principal in its IT Advisory Services practice . Rossi is the third ... market demand for strategic IT guidance grows, and the practice continues to expand.     , ...
(Date:1/17/2017)... ... 2017 , ... Physicians Education Review®, LCC (PER®) announces philanthropist, ... the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 at the ... said, “We are delighted to have Sandra Lee join us as our keynote ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Many people make New Year’s resolutions or ... Robert Mondavi is making it easier for people who want to kick off 2017 ... new and existing patients. , These special offers include: , , ...
(Date:1/16/2017)... ... January 17, 2017 , ... To ... internationally recognized leader in the fast-casual category, announces a hearty and wholesome Winter ... Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 17, 2017 Research and Markets has ... 2017 - 2024" report to their offering. ... This new report revisits the ... that was issued in May of 2015. Self-healing is an area ... previous analysis we projected a market potential of $2.7 billion ($US) ...
(Date:1/17/2017)... Management to Discuss Acquisition of ... KIT-302 Development On Track For An NDA ... Q1 2017   ... Holdings Ltd. (NASDAQ: KTOV ; TASE: KTOV), an innovative biopharmaceutical company, ... rd at 8:30am Eastern Time to discuss the recent acquisition of a ...
(Date:1/17/2017)... 17, 2017  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, plans to ... 31, 2016 after the market closes on Wednesday, February ... 5:00 p.m. ET that day to discuss those results. ... (877) 407-8037 or (201) 689-8037.  For 72 hours following ...
Breaking Medicine Technology: